The Standard Curve — Essays

How to Actually Read a Vendor

Ernesto Rodríguez Soto — Fri, 26 Jun 2026 00:00:00 GMT

The previous essays argued that the East–West divide is real but misunderstood, and that Mexico exposes the truth of it. This one is the practical payoff: a method you can actually use when a platform is in front of you and a decision is due. Think of it as the calibration protocol for a vendor — seven readings, each meaningless alone, useful only when weighted against what your laboratory needs.

The discipline is not to score every vendor the same way. It is to decide, before any salesperson walks in, which of these readings matter most for the specific decision at hand — and then refuse to be talked out of your own weighting.

1. Total cost over the contract, not the sticker

Build the real number across the full comodato horizon: reagents at realistic volumes, controls and calibrators, service, consumables, the currency exposure, and the cost of expected downtime. A higher reagent price with rock-solid uptime can beat a cheaper one that strands you twice a year. The sticker price is the least informative number in the entire evaluation; treat anyone who anchors you to it with suspicion.

2. Reagent lock-in and menu fit

How closed is the system, and what does that closure cost you in leverage over the next five years? An open or semi-open design is worth a real premium in flexibility — but only if you will use it. Conversely, a closed system is acceptable if the menu genuinely fits your test catalogue and the relationship is sound. Map your actual workload against the menu, not the brochure’s menu, and count the assays you will run weekly versus the ones that merely look impressive on the list.

3. Regulatory track record — for your market

Not all clearances are equal, and not all of them are relevant to you. What matters is the registration status where you operate and the depth of the record behind it. A platform rich in one regulatory system and thin in another is telling you where it has invested. Read that honestly rather than treating any single approval as a universal seal.

4. Evidence depth — for the assays that matter

You do not need a thick correlation dossier for every analyte. You need it for the ones where a patient is monitored over time against a fixed reference interval, where a clinical decision turns on a small difference, or where a pathologist will reasonably demand it. For well-characterised, robust analytes the evidence bar is genuinely lower, and insisting on a Western-grade dossier there is paying for assurance you will never cash. Match the evidence you demand to the clinical stakes of each test.

Demand deep evidence where a wrong number hurts a patient, and demand sharp pricing where it does not. Most buyers get this exactly backwards — over-paying on routine analytes and under-scrutinising the ones that actually carry risk.

5. Service network and parts logistics — in your country

This is the variable a specification sheet is structurally incapable of showing you, and it is frequently the one that decides whether you were right. Ask concrete, local questions. Where is the nearest engineer? What is the real mean time to repair, not the promised one? Where do critical parts physically sit, and how many of these instruments are already running near you? A young network is not disqualifying, but it must be priced into reading number one — and it usually is not.

6. Supply-chain resilience

Trace, as far as you can, the path that keeps reagents and parts physically in front of you. How many links, how many borders, how much buffer? A magnificent platform with a fragile supply path is a future emergency wearing good marketing. This reading has quietly become one of the most important, and it is still one of the least examined.

7. The human factor

Finally, and least quantifiably: who actually answers when something breaks at the worst possible moment? The local commercial and technical team — their competence, their candour, their willingness to own a problem — does more to determine your lived experience than any spec on the sheet. I have watched this single variable rescue a mediocre platform and sink an excellent one.

Putting it together

Notice that none of the seven readings is “is it Asian or Western.” That question has dissolved into these seven, which is exactly the point. A serious evaluation weights them to the decision, scores each vendor against the weighting, and lets the badge fall wherever the numbers put it. Sometimes that is a Western incumbent earning its premium honestly. Sometimes it is an Asian platform that is simply the correct answer. More often than anyone admits, it is whichever one came with the better local partner.

Run the readings. Weight them yourself. Then trust the curve over the brochure — every time.

Mexico, Where the Philosophies Collide

Ernesto Rodríguez Soto — Thu, 18 Jun 2026 00:00:00 GMT

There are markets where the East–West contest is still theoretical — where one philosophy dominates so completely that the other never gets a fair hearing. Mexico is not one of them. Here the two bets are placed against each other, in public, on real money, every week. If you want to know which vendor claims survive contact with reality, this is the bench to watch.

Three features of our market make it such an honest test.

The comodato turns a sale into a marriage

Almost nothing of consequence is bought outright here. The dominant structure is the comodato — the instrument is placed at little or no upfront cost, and the laboratory commits to buying reagents over a multi-year horizon. It is the razor-and-blade model written into a contract, and it changes everything about how value reveals itself.

When the analyzer is effectively free at the door, the sticker price stops being the question. The real question becomes the cost and reliability of the reagent stream over three, four, five years — and the quality of the relationship across that span. This is where Asian platforms have become genuinely formidable — though the mechanism is rarely the one people picture. The Chinese manufacturer does not structure the comodato; it sells to the local distributor directly from the factory, and it is the distributor who decides to place the instrument on comodato and carries its financial weight — viable precisely because the underlying cost is so low. In return, that same distributor takes on the maintenance, the spare-parts inventory, and the reagent supply. The lower reagent cost compounds powerfully over a long contract. It is also where the Western evidence-and-service premium has to earn itself continuously, month after month, rather than coasting on the day the purchase order was signed.

The tender rewards the cheapest bid and punishes the winner

A large share of volume moves through public-sector tenders, and a tender is a blunt instrument. It is written to reward the lowest compliant bid, which structurally favours the Asian price bet. But the same institution that awarded on price will then measure the winner ruthlessly on turnaround time, downtime, and reagent supply continuity — the very dimensions a specification sheet cannot capture.

A tender selects on the day’s price and is judged on the year’s uptime. The gap between those two things is where reputations are actually made and lost.

I have watched a low bid win a contract and then quietly lose money for everyone, because nobody had priced in the cost of a service network that was not yet built out for the installed base it suddenly had to support. I have also watched an incumbent lose a tender it deserved to lose, because it had grown comfortable charging for a service level it was no longer reliably delivering. The tender does not reward virtue. It rewards whoever priced the true cost correctly — and that is a harder calculation than either side likes to admit.

The peso and the supply chain are part of the spec

Two variables that barely register in a glossy comparison dominate the lived experience here. The first is the exchange rate: reagent streams priced in dollars carry a currency exposure that a five-year comodato turns into a real risk, and the way a vendor handles that exposure tells you a great deal about the partnership. The second is supply-chain resilience, a lesson the whole industry relearned the hard way and then, predictably, began to forget. A platform with a magnificent menu and a fragile path to keep reagents and parts physically on Mexican soil is not a bargain; it is a future emergency with good marketing.

What the collision teaches

The pattern that emerges from all this is not “Asian wins” or “Western wins.” It is that the distributor and the service relationship are doing far more of the work than the badge on the instrument. A first-rate local partner can make an Asian platform sing and an aging Western one age gracefully; an absentee one can strand either. The country exposes, again and again, that buyers who chose on the analyzer alone chose on the least durable variable in the system.

That is the gift of writing from here. Mexico does not let either philosophy hide behind a brochure. It puts both bets on the table, runs them for years, and shows you the result. All I have to do is keep reading the curve.

Two Philosophies of the Analyzer

Ernesto Rodríguez Soto — Wed, 10 Jun 2026 00:00:00 GMT

If you want to start an unproductive argument in this industry, ask whether Chinese analyzers are “as good as” the Western ones. The question is a trap, because good is doing too much work. Good at what? Cheap to run? Defensible in a tender? Backed by a decade of peer-reviewed correlation studies? Available next Tuesday? These are different virtues, and no single platform maximises all of them. The honest move is to stop ranking and start describing. When you do, two distinct design philosophies come into focus.

The Western bet: evidence, standardisation, and the long game

The established Western houses — and I will include the premium Japanese platforms here, because commercially they behave the same way — are built around a particular conviction: that the durable source of value in diagnostics is trust, and that trust is manufactured slowly.

So they invest in the things that compound over decades. Calibrator hierarchies traceable to international reference methods. Correlation dossiers thick enough to satisfy the most conservative pathologist. Regulatory track records that make a hospital’s risk committee comfortable. Middleware and connectivity that has survived contact with a thousand laboratory information systems. A global service infrastructure with parts depots and trained engineers. This is genuinely expensive to build, and the price of the reagents reflects it.

The shadow side of this philosophy is equally consistent. Closed systems, defended hard, because the reagent stream is the business model. Slow iteration, because every change drags a regulatory and validation tail behind it. And a quiet temptation to charge for the brand long after the engineering lead has narrowed. The same conservatism that protects a teaching hospital can fleece a routine lab that is paying for assurances it will never need to cash.

The Asian bet: speed, price, menu, and flexibility

The newer Asian manufacturers — the Chinese houses most visibly, but also a wave of Korean players — are built around a different conviction: that the market is moving fast, that access beats prestige, and that the way to win is to give more laboratories more capability sooner.

So they optimise the other variables. Aggressive pricing, often structured to make the comodato maths irresistible. Menus that expand at a startling rate, because the regulatory path at home rewards speed. Open or semi-open system designs that hand the laboratory flexibility the incumbents withhold. Hardware that is frequently excellent, because the manufacturing base behind it is now world-class. And commercial teams genuinely willing to localise, customise, and answer the phone.

A decade ago the trade-off was quality for price. Today the trade-off is usually evidence and standardisation for speed and flexibility. That is a completely different bargain — and for many laboratories, a better one.

The shadow side here is just as real. The published clinical evidence, while growing fast, is often thinner and more recent than a conservative buyer wants — more CE and NMPA than FDA, more in-house than independent. Standardisation and lot-to-lot harmonisation deserve scrutiny, especially for assays where a patient is followed over time against a fixed reference interval. Connectivity can be quirky. And the service-and-parts network in a specific country may be young, which is precisely the variable a glossy specification sheet hides.

Reading the two bets correctly

Notice what this reframing does. It stops you asking “which brand is better” and starts you asking “which bet matches my laboratory.”

A reference laboratory running endocrinology assays where patients are monitored for years against tight reference intervals should weight standardisation and evidence heavily — and may rationally pay the Western premium. A high-volume routine chemistry operation drowning in cost pressure, running well-characterised analytes, may find that the Asian bet is not a compromise at all but the obviously correct engineering and financial choice. The same hospital might reasonably make both decisions, in different departments, on the same afternoon.

The mistake is never choosing an Asian platform, and it is never choosing a Western one. The mistake is choosing either one for the wrong reason — buying prestige you will not use, or buying a price that quietly mortgages your uptime. Both philosophies are coherent. Both are sold, relentlessly, to laboratories they do not fit.

The job — mine, and yours if you sit on the buying side — is to know your own laboratory well enough to know which bet you are actually placing. Everything else is the vendor’s preferred story, told beautifully, and uncalibrated.

Reading the Standard Curve

Ernesto Rodríguez Soto — Tue, 02 Jun 2026 00:00:00 GMT

Every lab technologist learns the same humbling lesson early: the instrument never gives you the answer. It gives you a signal — a voltage, a count, a flash of light — and the signal means nothing until you have run a standard curve to relate it to a known quantity. Skip the calibration and the most sophisticated analyzer in the world will hand you a confident, beautifully formatted, completely wrong result.

I have come to believe the diagnostics market works exactly the same way, and that almost nobody is running the curve.

We are flooded with signal. Glossy brochures, KOL webinars, tender specifications written to favour one platform, WhatsApp forwards claiming a Chinese analyzer is either a miracle or a menace. Each of these is a raw reading. None of them is calibrated. And the calibration standard most of the industry still reaches for is a relic: Western brands are quality, Asian brands are cheap. I want to take that standard out of service.

The map stopped matching the territory

When I started, the shorthand was roughly accurate. The serious immunoassay and clinical chemistry platforms came from a handful of Western houses. The instruments arriving from Asia were often genuine copies — reverse-engineered, underspecified, thin on evidence, and sold almost entirely on price. If you bought one, you knew what you were doing and why.

That world is gone. It did not erode; it inverted. Today a chemiluminescence analyzer from Shenzhen can post precision and throughput that would have been flagship numbers for a Western brand a decade ago. Asian manufacturers ship full laboratory automation tracks, expand their assay menus at a cadence the incumbents cannot match, and — crucially — design their commercial terms around how emerging markets actually buy. Meanwhile some Western platforms coast on reputation, defend closed reagent systems with the enthusiasm of a printer company, and iterate at the speed of a regulated giant.

The interesting question is no longer who is better. It is what each side is optimising for — and whether that happens to match what your laboratory actually needs.

That is the curve I want to build. Not East versus West as a loyalty test, but East and West as two coherent, internally rational design philosophies that make different bets. One bets on evidence, standardisation, and the long regulatory game. The other bets on speed, price, menu, and flexibility. Neither bet is stupid. Each is exactly right for some laboratories and exactly wrong for others.

Why Mexico is the right desk to write from

You could observe this collision from anywhere, but Mexico is where it happens with the gloves off. We are price-sensitive enough that Asian platforms get a serious hearing, sophisticated enough that the clinical questions are real, and structured around the comodato — the reagent-rental model — in a way that turns every purchase into a multi-year relationship rather than a one-time transaction. A public tender here will reward the cheapest compliant bid and then punish the winner mercilessly for every hour of downtime. There is no better stress test for a vendor’s true value.

From this desk I have watched a Western platform justify a premium it had genuinely earned, and I have watched another charge that premium for a reputation it was quietly living off. I have watched an Asian analyzer outperform its price and its prejudice, and I have watched another arrive with a spectacular menu and a service network that evaporated the moment a board failed. The lesson is never the flag on the box. The lesson is always in the calibration.

What you will find here

This notebook is not a buyer’s guide and it is not a hit list. It is a set of standard curves — frameworks for turning the noisy signal of this industry into numbers you can actually act on. Some posts will be argument: a thesis about where the two philosophies are heading. Some will be field notes from the Mexican bench. Some will be plain method: how to read a vendor without your prejudices reading it for you.

I will be fair, because fairness is more useful than fireworks, and because I work with all of these companies and respect the good engineers inside every one of them. But fair is not the same as soft. Where a platform is overpriced for what it delivers, I will say so. Where a cheap analyzer is a false economy waiting to strand a lab, I will say that too.

The signal is loud. Let us calibrate.